Stocks Overview

LAST PRICE
12.8800
TODAY'S CHANGE (%)
Trending Up0.1800 (1.4173%)

Bid / Lots
---/ ---
Ask / Lots
---/ ---
Open / Previous Close
12.7600 / 12.7000
Day Range
Low 12.7000
High 13.1332
52 Week Range
Low 10.6001
High 20.7000
Volume
489,191
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Friday's close: 12.7
Time	Volume	URGN
09:32 ET	3637	12.76
09:33 ET	600	12.765
09:35 ET	300	12.7356
09:37 ET	1217	12.78
09:44 ET	100	12.765
09:46 ET	400	12.74
09:48 ET	200	12.73
09:50 ET	200	12.74
09:51 ET	100	12.76
09:53 ET	6696	12.735
09:55 ET	300	12.71
09:57 ET	1725	12.7
10:00 ET	500	12.73
10:02 ET	600	12.74
10:04 ET	17048	12.84
10:06 ET	1125	12.8
10:08 ET	6133	12.9
10:09 ET	1200	12.865
10:11 ET	2496	12.875
10:13 ET	5257	12.89
10:15 ET	516	12.895
10:18 ET	5244	12.92
10:22 ET	250	12.9238
10:24 ET	1800	12.945
10:26 ET	1900	12.97
10:27 ET	3320	12.9907
10:31 ET	8892	13.065
10:33 ET	10509	13.05
10:36 ET	10318	13.09
10:38 ET	1000	13.0596
10:40 ET	7075	13.045
10:42 ET	400	13.0014
10:44 ET	2696	13.005
10:47 ET	19156	13
10:49 ET	1359	12.98
10:51 ET	2836	13.09
10:54 ET	7531	13.105
10:56 ET	19824	13
10:58 ET	7292	12.96
11:00 ET	1116	13
11:03 ET	100	12.95
11:05 ET	2592	12.9927
11:12 ET	800	12.975
11:14 ET	200	12.94
11:16 ET	900	12.94
11:20 ET	1000	12.99
11:21 ET	500	12.98
11:23 ET	200	12.97
11:25 ET	100	12.97
11:32 ET	100	12.95
11:34 ET	1000	12.93
11:36 ET	229	12.8883
11:41 ET	3329	12.87
11:43 ET	100	12.875
11:57 ET	872	12.92
11:59 ET	100	12.94
12:06 ET	19075	12.9
12:08 ET	100	12.875
12:12 ET	500	12.88
12:14 ET	100	12.885
12:15 ET	504	12.914
12:19 ET	350	12.88
12:21 ET	100	12.865
12:26 ET	8078	12.84
12:28 ET	4780	12.86
12:30 ET	11074	12.865
12:32 ET	482	12.85
12:33 ET	405	12.85
12:37 ET	100	12.88
12:39 ET	660	12.85
12:44 ET	3745	12.85
12:46 ET	980	12.85
12:48 ET	8663	12.915
12:50 ET	3472	12.8945
12:53 ET	896	12.9
01:00 ET	100	12.86
01:02 ET	400	12.85
01:08 ET	100	12.81
01:09 ET	100	12.8
01:11 ET	120	12.82
01:13 ET	100	12.8
01:18 ET	600	12.8
01:20 ET	100	12.82
01:22 ET	100	12.79
01:26 ET	2340	12.765
01:29 ET	100	12.78
01:31 ET	2170	12.77
01:33 ET	5788	12.86
01:36 ET	100	12.87
01:38 ET	150	12.86
01:40 ET	100	12.85
01:42 ET	967	12.86
01:44 ET	4440	12.85
01:49 ET	100	12.86
01:51 ET	1190	12.86
01:54 ET	9954	12.94
01:58 ET	100	12.95
02:02 ET	515	12.99
02:03 ET	2651	13.02
02:05 ET	120	13.01
02:07 ET	493	13.01
02:09 ET	500	13.02
02:12 ET	1013	13.02532
02:14 ET	3546	12.96
02:16 ET	100	12.91
02:18 ET	1200	12.91
02:20 ET	2494	12.905
02:23 ET	127	12.91
02:30 ET	240	12.91
02:32 ET	120	12.91
02:34 ET	3245	12.85
02:36 ET	2256	12.86
02:38 ET	100	12.86
02:39 ET	100	12.865
02:45 ET	3592	12.875
02:48 ET	883	12.9
02:50 ET	100	12.9
02:52 ET	256	12.875
02:54 ET	1664	12.86
02:59 ET	840	12.88
03:01 ET	1200	12.86
03:03 ET	300	12.865
03:06 ET	100	12.84
03:08 ET	641	12.91
03:10 ET	100	12.86
03:12 ET	100	12.85
03:14 ET	693	12.87
03:15 ET	100	12.84
03:17 ET	6671	12.875
03:24 ET	100	12.865
03:26 ET	120	12.89
03:28 ET	871	12.86
03:32 ET	1204	12.85
03:33 ET	529	12.865
03:35 ET	2017	12.88
03:37 ET	100	12.88
03:39 ET	1013	12.88
03:42 ET	765	12.89
03:44 ET	1650	12.89
03:46 ET	950	12.9
03:48 ET	200	12.88
03:50 ET	1800	12.885
03:51 ET	2020	12.88
03:53 ET	1849	12.89
03:55 ET	16660	12.95
03:57 ET	11871	12.9
04:00 ET	51175	12.88

Data delayed at least 15 minutes.

Yesterday
- UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs, from 19 hours ago by Dow Jones
  19 hours ago by Dow Jones
Nov 26, 2024
- New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO(R), from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 6, 2024
- DJ UroGen Pharma Is Maintained at Buy by EF Hutton, from 11:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
  11:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
- *DJ UroGen Pharma 3Q Loss/Shr 55c >URGN, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
- UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesURGN Urogen Pharma Ltd	543.5M	-4.1x	---
United StatesYMAB Y-mAbs Therapeutics Inc	528.1M	-21.8x	---
United StatesCDXC Chromadex Corp	577.5M	399.4x	---
United StatesRGNX Regenxbio Inc	495.5M	-2.0x	---
United StatesGRAL Grail Inc	629.3M	0.0x	---
United StatesSAGE SAGE Therapeutics Inc	354.2M	-1.0x	---
As of 2024-12-03

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Contact Information

Headquarters: 9 Ha'ta'asiya StRA'ANANA, Israel 4365007
Phone: ---
Fax: ---

Executives

Independent Chairman of the Board: Arie Belldegrun
President, Chief Executive Officer, Director: Elizabeth Barrett
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer: Christopher Degnan
Chief Compliance Officer, General Counsel, Corporate Secretary: Jason Smith
Chief Commercial Officer: David Lin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$543.5M
Revenue (TTM)	$89.4M
Shares Outstanding	42.2M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.07
EPS	$-3.14
Book Value	$-2.01
P/E Ratio	-4.1x
Price/Sales (TTM)	6.1
Price/Cash Flow (TTM)	---
Operating Margin	-93.70%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Urogen Pharma Ltd
NASDAQ:URGNUnited States

Search Criteria

Charts

Recent News

Yesterday

UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs, from 19 hours ago by Dow Jones

Nov 26, 2024

New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO(R), from 8:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 6, 2024

DJ UroGen Pharma Is Maintained at Buy by EF Hutton, from 11:30AM ET on Wednesday Nov 06, 2024 by Dow Jones

*DJ UroGen Pharma 3Q Loss/Shr 55c >URGN, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar